192 related articles for article (PubMed ID: 27252412)
41. Toll-like receptor agonist imiquimod facilitates antigen-specific CD8+ T-cell accumulation in the genital tract leading to tumor control through IFNγ.
Soong RS; Song L; Trieu J; Knoff J; He L; Tsai YC; Huh W; Chang YN; Cheng WF; Roden RB; Wu TC; Trimble CL; Hung CF
Clin Cancer Res; 2014 Nov; 20(21):5456-67. PubMed ID: 24893628
[TBL] [Abstract][Full Text] [Related]
42. A novel therapeutic vaccine composed of a rearranged human papillomavirus type 16 E6/E7 fusion protein and Fms-like tyrosine kinase-3 ligand induces CD8
Li J; Chen S; Ge J; Lu F; Ren S; Zhao Z; Pu X; Chen X; Sun J; Gu Y
Vaccine; 2017 Nov; 35(47):6459-6467. PubMed ID: 29029939
[TBL] [Abstract][Full Text] [Related]
43. Assessing the reduction of viral infectivity in HPV16/18-positive women after one, two, and three doses of Gardasil-9 (RIFT): Study protocol.
López-Codony V; de Andrés-Pablo Á; Ferrando-Díez A; Fernández-Montolí ME; López-Querol M; Tous S; Ortega-Expósito C; Torrejón-Becerra JC; Pérez Y; Ferrer-Artola A; Sole-Sedeno JM; Grau C; Rupérez B; Saumoy M; Sánchez M; Peremiquel-Trillas P; Bruni L; Alemany L; Bosch FX; Pavón MA
PLoS One; 2024; 19(5):e0304080. PubMed ID: 38768231
[TBL] [Abstract][Full Text] [Related]
44. Immunogenicity and safety of an E. coli-produced bivalent human papillomavirus (type 16 and 18) vaccine: A randomized controlled phase 2 clinical trial.
Wu T; Hu YM; Li J; Chu K; Huang SJ; Zhao H; Wang ZZ; Yang CL; Jiang HM; Wang YJ; Lin ZJ; Pan HR; Sheng W; Wei FX; Li SW; Wang Y; Zhu FC; Li CG; Zhang J; Xia NS
Vaccine; 2015 Jul; 33(32):3940-6. PubMed ID: 26100924
[TBL] [Abstract][Full Text] [Related]
45. [Cervical carcinoma and the vaccination experience with Cervarix].
Berberova M
Akush Ginekol (Sofiia); 2012; 51 Suppl 1():4-5. PubMed ID: 23236670
[No Abstract] [Full Text] [Related]
46. Antibody response for L1, E6 and E7 HPV 16 and HPV 18 antigens in Tunisian women with cervical cancer and controls.
Achour M; Zeghal D; Kochbati L; Kahla S; Zouari F; Maalej M; Oueslati R
J Immunoassay Immunochem; 2008; 29(3):266-80. PubMed ID: 18569375
[TBL] [Abstract][Full Text] [Related]
47. Immuno-Stimulating Peptide Derived from HMGB1 is More Effective Than the N-Terminal Domain of Gp96 as an Endogenous Adjuvant for Improvement of Protein Vaccines.
Talebi S; Bolhassani A; Azad TM; Arashkia A; Modaresi MH
Protein Pept Lett; 2017; 24(3):190-196. PubMed ID: 28000571
[TBL] [Abstract][Full Text] [Related]
48. Immunogenicity and safety of the bivalent HPV vaccine in female patients with juvenile idiopathic arthritis: a prospective controlled observational cohort study.
Heijstek MW; Scherpenisse M; Groot N; Tacke C; Schepp RM; Buisman AM; Berbers GA; van der Klis FR; Wulffraat NM
Ann Rheum Dis; 2014 Aug; 73(8):1500-7. PubMed ID: 23723319
[TBL] [Abstract][Full Text] [Related]
49. Sustained efficacy and immunogenicity of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine: analysis of a randomised placebo-controlled trial up to 6.4 years.
; Romanowski B; de Borba PC; Naud PS; Roteli-Martins CM; De Carvalho NS; Teixeira JC; Aoki F; Ramjattan B; Shier RM; Somani R; Barbier S; Blatter MM; Chambers C; Ferris D; Gall SA; Guerra FA; Harper DM; Hedrick JA; Henry DC; Korn AP; Kroll R; Moscicki AB; Rosenfeld WD; Sullivan BJ; Thoming CS; Tyring SK; Wheeler CM; Dubin G; Schuind A; Zahaf T; Greenacre M; Sgriobhadair A
Lancet; 2009 Dec; 374(9706):1975-85. PubMed ID: 19962185
[TBL] [Abstract][Full Text] [Related]
50. A phase 1/2a, dose-escalation, safety and preliminary efficacy study of oral therapeutic vaccine in subjects with cervical intraepithelial neoplasia 3.
Park YC; Ouh YT; Sung MH; Park HG; Kim TJ; Cho CH; Park JS; Lee JK
J Gynecol Oncol; 2019 Nov; 30(6):e88. PubMed ID: 31576684
[TBL] [Abstract][Full Text] [Related]
51. HPV-16 E7-Specific Cellular Immune Response in Women With Cervical Intraepithelial Lesion Contributes to Viral Clearance: A Cross-Sectional and Longitudinal Clinical Study.
Zhang L; Shi X; Zhang Q; Mao Z; Shi X; Zhou J; Jian A; Zhu R; Jiang S; Lu W
Front Immunol; 2021; 12():768144. PubMed ID: 35095843
[TBL] [Abstract][Full Text] [Related]
52. HPV16/18 E7-pulsed dendritic cell vaccination in cervical cancer patients with recurrent disease refractory to standard treatment modalities.
Santin AD; Bellone S; Palmieri M; Ravaggi A; Romani C; Tassi R; Roman JJ; Burnett A; Pecorelli S; Cannon MJ
Gynecol Oncol; 2006 Mar; 100(3):469-78. PubMed ID: 16249018
[TBL] [Abstract][Full Text] [Related]
53. Combined prophylactic and therapeutic intranasal vaccination against human papillomavirus type-16 using different adeno-associated virus serotype vectors.
Nieto K; Kern A; Leuchs B; Gissmann L; Müller M; Kleinschmidt JA
Antivir Ther; 2009; 14(8):1125-37. PubMed ID: 20032542
[TBL] [Abstract][Full Text] [Related]
54. Comparison of six cell penetrating peptides with different properties for in vitro and in vivo delivery of HPV16 E7 antigen in therapeutic vaccines.
Shahbazi S; Bolhassani A
Int Immunopharmacol; 2018 Sep; 62():170-180. PubMed ID: 30015237
[TBL] [Abstract][Full Text] [Related]
55. Immunogenicity of bivalent HPV vaccine among partially vaccinated young adolescent girls in Uganda.
LaMontagne DS; Mugisha E; Pan Y; Kumakech E; Ssemaganda A; Kemp TJ; Cover J; Pinto LA; Safaeian M
Vaccine; 2014 Oct; 32(47):6303-11. PubMed ID: 25218297
[TBL] [Abstract][Full Text] [Related]
56. MenACWY-TT is immunogenic when co-administered with Tdap and AS04-HPV16/18 in girls and young women: Results from a phase III randomized trial.
Rivera L; Chanthavanich P; Põder A; Suryakiran PV; Jastorff A; Van der Wielen M
Vaccine; 2018 Jun; 36(27):3967-3975. PubMed ID: 29789243
[TBL] [Abstract][Full Text] [Related]
57. Polymeric nanoparticles for co-delivery of synthetic long peptide antigen and poly IC as therapeutic cancer vaccine formulation.
Rahimian S; Fransen MF; Kleinovink JW; Christensen JR; Amidi M; Hennink WE; Ossendorp F
J Control Release; 2015 Apr; 203():16-22. PubMed ID: 25660830
[TBL] [Abstract][Full Text] [Related]
58. Evaluation of bivalent human papillomavirus (HPV) vaccine safety and tolerability in a sample of 25 year old Tuscan women.
Levi M; Bonanni P; Burroni E; Bechini A; Boccalini S; Sani C; Bonaiuti R; Indiani L; Azzari C; Lippi F; Carozzi F;
Hum Vaccin Immunother; 2013 Jul; 9(7):1407-12. PubMed ID: 23571176
[TBL] [Abstract][Full Text] [Related]
59. Four-year follow-up of the immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine when administered to adolescent girls aged 10-14 years.
Schwarz TF; Huang LM; Medina DM; Valencia A; Lin TY; Behre U; Catteau G; Thomas F; Descamps D
J Adolesc Health; 2012 Feb; 50(2):187-94. PubMed ID: 22265115
[TBL] [Abstract][Full Text] [Related]
60. Skin reactions to human papillomavirus (HPV) 16 specific antigens intradermally injected in healthy subjects and patients with cervical neoplasia.
van den Hende M; van Poelgeest MI; van der Hulst JM; de Jong J; Drijfhout JW; Fleuren GJ; Valentijn AR; Wafelman AR; Slappendel GM; Melief CJ; Offringa R; van der Burg SH; Kenter GG
Int J Cancer; 2008 Jul; 123(1):146-52. PubMed ID: 18404684
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]